We consider that there may be shared genetic etiology between circulating ACE2 levels and AD, which may contribute to explain the highest risk of COVID‐19 infection, hospitalization, and mortality in preexisting diagnosis of AD, as well as the increased risk of AD in COVID‐19 patients. Here, ACE2 is linked to COVID-19.